NCT01524601

The Rosuvastatin In TrAnsplant Recipients Study

The RITA-study -- An Open Study to Evaluate the Blood Lipid Lowering Effect of Rosuvastatin Versus Fluvastatin and the Bilateral Interaction Between Everolimus and Rosuvastatin in Renal Transplant Recipients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: University of Oslo School of Pharmacy · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Renal transplant recipients need life long immunosuppression and one of the new drugs is everolimus. Everolimus is a potent immunosuppressive drug and one of the main side-effects are increased blood cholesterol levels. Many renal transplant recipients are treated with a cholesterol lowering agent, mainly fluvastatin. Rosuvastatin is a new cholesterol lowering drug on the market with a potential higher cholesterol lowering potency. In the present study the investigators will examine the hypothesis that rosuvastatin reduce cholesterol levels more than fluvastatin in renal transplant patients.

Conditions

• Disorder Related to Renal Transplantation
• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Rosuvastatin	20 mg rosuvastatin for 4 weeks

Timeline

• Start date: 2012-02-01
• Primary completion: 2012-10-01
• Completion: 2012-10-01
• First posted: 2012-02-02
• Last updated: 2012-10-12

Locations

1 site across 1 country: Norway